First‐in‐man study of ACT‐453859, a potent CRTH2 antagonist—Is the metabolite formation influenced by a polymorphic enzyme?

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|12|1432-1432

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.12, 2015-12, pp. : 1432-1432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 787-797

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP2C9 involvement in ACT‐453859 metabolism

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1433-1433

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the interleukin‐11 receptor α in metastatic prostate cancer: A first‐in‐man study

By  

CANCER, Vol. 121, Iss. 14, 2015-07 ,pp. : 2411-2421

John Wiley & Sons Inc

Access to resources Recommend Favorite

First‐in‐Man Study of Dedicated Bifurcation Sirolimus‐eluting Stent: 12‐month Results of BiOSS LIM® Registry

By  

JOURNAL OF INTERVENTIONAL CARDIOLOGY, Vol. 28, Iss. 1, 2015-02 ,pp. : 51-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy

By  

International Archives of Allergy and Immunology, Vol. 166, Iss. 1, 2015-02 ,pp. : 41-51

Karger

Access to resources Recommend Favorite